Patients report positive changes across all measured areas of daily living

SEOUL, South Korea, Oct. 12, 2026 /PRNewswire/ -- After showing meaningful improvements in both the movement and daily lives of people with Parkinson's disease, and new drug will be submitted for regulatory approval.

Patients with Parkinson's, who can have difficulty moving, reported improvements in measures of daily living from the potential treatment, which also restored their 'good' movement time for an average of 36 more minutes a day than using their regular medication alone. Following these promising ARISE clinical trial results, which were presented at the International Congress of Parkinson's Disease and Movement Disorders, the drug, solengepras, will now be submitted to the Federal Drug Administration (FDA) in the United States for approval.

"It is especially encouraging that in addition to the improvements in the good 'on' time, the patients themselves felt overall benefits in their usual motor function," said Ron Postuma, Chair of the MDS International Congress Scientific Program Committee. "In fact, the self-reported improvements are higher than you might expect for a 36-minute on time difference, which shows there is still more to explore about the possibilities of this drug."

Solengepras works differently than other drugs currently on the market, so its progress could also open the door for further innovations using similar techniques.

Drooling and saliva was the most significant self-reported change, and other outcomes included improved daytime sleepiness.

About the 2026 MDS International Congress of Parkinson's Disease and Movement Disorders®:

The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson's disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 2,000 scientific abstracts and provide a forum for education and collaboration on latest research and treatment findings.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society® (MDS), an international society of more than 12,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit www.movementdisorders.org.

SOURCE International Parkinson and Movement Disorder Society

Share this article

T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer

BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for the treatment of patients with brain metastases from lung cancer and breast cancer.

This is the second Phase 2 study of MT027 to receive FDA clearance. MT027 was previously cleared by the FDA to proceed with a Phase 2 study in recurrent glioblastoma, and has been granted Orphan Drug Designation (ODD) and Fast Track Designation (FTD). With two FDA-cleared Phase 2 programs, T-MAXIMUM has established a dual-indication portfolio for universal CAR-T therapy covering both primary and metastatic intracranial solid tumors.

Brain Metastases: An Unanswered Clinical Question Despite Advances in Systemic Therapy

Brain metastases commonly arise in patients with lung cancer, breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. International studies estimate that approximately 20% of cancer patients may develop brain metastases over the course of their disease, a proportion that can reach 20% to 40% among patients with advanced solid tumors.[1][2] For patients, this means far more than an additional lesion on imaging: brain metastases may be accompanied by headaches, seizures, and cognitive and motor impairment, directly affecting daily life and subsequent treatment options.

This is a truly global clinical challenge. In 2022, there were nearly 20 million new cancer cases worldwide, including nearly 2.5 million new cases of lung cancer and approximately 2.3 million new cases of female breast cancer – the two leading primary tumor types giving rise to brain metastases.[3] Asia accounts for roughly half of all new cancer cases globally;[4] in the United States, an estimated 200,000 to 300,000 patients are newly diagnosed with brain metastases each year.[2] This large patient population means brain metastasis is not a niche need, but a question that oncology worldwide must continue to answer.

Systemic therapies can help control disease throughout the body, but treatment of intracranial lesions often remains constrained by multiple factors, including the blood-brain barrier, tumor heterogeneity, and the need to preserve neurological function. This is especially true for patients who experience intracranial progression after prior therapy, for whom there remains a need for more treatment options that are validated intracranially while balancing safety and accessibility.

Consecutive Clinical Milestones Built on Long-Term Product and Translational Groundwork

MT027's recent series of regulatory milestones is no coincidence. It reflects an integrated capability across product, manufacturing, clinical development, and regulatory affairs built around intracranial solid tumors – one that is now advancing from early exploration toward more systematic clinical validation.

First, a foundation of clinical data. The company has accumulated sustained clinical experience in local delivery, repeat dosing, and safety monitoring for intracranial solid tumors. Years of clinical experience and data with MT027 have already led to two FDA-cleared Phase 2 programs. Data from an investigator-initiated trial (IIT) of MT026, a program built on the same platform, were published in Nature Communications in 2026: among 5 patients with recurrent high-grade glioma, 1 complete response and 3 partial responses were observed, for an objective response rate (ORR) of 80%, with no treatment-related Grade 3 or higher adverse events.

Early clinical data for MT027 in patients with refractory brain metastases from lung cancer were previously presented at the IASLC 2026 World Conference on Lung Cancer (WCLC 2026). Five heavily pretreated patients with no guideline-recommended subsequent treatment options completed treatment; among the 3 evaluable patients, 2 partial responses were observed. The safety profile was favorable, with no Grade 3 or higher adverse events and no graft-versus-host disease (GvHD). These rigorous exploratory clinical studies provide an important basis for the clinical translation of allogeneic, locally delivered CAR-T therapy in intracranial solid tumors.

Second, a well-defined manufacturing process. MT027 is manufactured using a fully non-viral gene-editing process – a generational departure from the industry's mainstream lentiviral vector approach – offering potential advantages in product safety, batch-to-batch consistency, and cost control. The manufacturing process was established and locked prior to entering Phase 2 clinical development.

Third, leadership measured not only by getting there first, but by advancing systematically. For an innovative cell therapy company, leadership in regulatory progress comes from coordinated advancement across product, manufacturing, clinical development, and regulatory strategy. MT027's consecutive entry into FDA-cleared Phase 2 clinical development demonstrates T-MAXIMUM's ability to translate its prior groundwork into a repeatable and scalable clinical development capability.

Management Commentary

"Receiving FDA clearance for two consecutive Phase 2 studies of MT027 marks a pivotal step built on our sustained work in intracranial solid tumors. From glioma to brain metastases, we have always let the data speak and put clinical value first. Going forward, we will continue to rigorously evaluate the product's safety and potential clinical value through well-designed clinical studies, steadily advancing product supply, clinical execution, and the generation of key data, as we explore new possibilities for patients who lack effective treatment options."

About MT027

MT027 is an investigational, B7-H3-targeted universal (allogeneic) CAR-T cell therapy developed by T-MAXIMUM using a fully non-viral gene-editing process and administered via local intracranial delivery. MT027 has received FDA Orphan Drug Designation and Fast Track Designation and is being evaluated in FDA-cleared Phase 2 studies in recurrent glioblastoma and in brain metastases from lung cancer and breast cancer.

About T-MAXIMUM PHARMACEUTICAL

T-MAXIMUM PHARMACEUTICAL is a clinical-stage cell therapy company focused on developing universal (allogeneic) CAR-T therapies for intracranial solid tumors with high unmet medical need, including recurrent glioblastoma and brain metastases. Through engineered cell therapies, local delivery strategies, and clinical translation capabilities, the Company is advancing more accessible treatment approaches with the potential to support repeat dosing. Its lead program, MT027, is a B7-H3-targeted universal CAR-T therapy that has received FDA clearance to initiate Phase 2 clinical studies in recurrent glioblastoma and brain metastases. MT027 has also received Orphan Drug Designation (ODD) in high-grade glioma and Fast Track Designation (FTD) for recurrent or progressive glioblastoma. T-MAXIMUM is working to translate its accumulated capabilities in product development, manufacturing, and clinical execution into continued innovation across both primary and metastatic intracranial solid tumors, with the goal of creating new possibilities for patients with limited treatment options.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the clinical development, potential therapeutic benefits, manufacturing advantages, and regulatory progress of MT027 and other product candidates. These statements are based on current expectations and are subject to risks and uncertainties, including those inherent in clinical development, regulatory review, and manufacturing, that could cause actual results to differ materially. Early clinical results from small numbers of patients may not be predictive of results in larger studies. MT027 is an investigational product, and its safety and efficacy have not been established. T-MAXIMUM undertakes no obligation to update any forward-looking statement, except as required by law.

References

SOURCE T-MAXIMUM PHARMACEUTICAL

Share this article

DELRAY BEACH, Fla., Oct. 12, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Oxygen Scavenger Market is expected to reach USD 4.99 billion by 2031 from USD 3.49 billion in 2026, at a CAGR of 7.4% during the forecast period.

Browse 260 market data Tables and 60 Figures spread through 330 Pages and in-depth TOC on 'Oxygen Scavenger Market - Global Forecast to 2031'

Oxygen Scavenger Market Size & Forecast:

- Market Size Available for Years: 2025-2031

- 2026 Market Size: USD 3.49 billion

- 2031 Projected Market Size: USD 4.99 billion

- CAGR (2026-2031): 7.4%

Oxygen Scavenger Market Trends & Insights:

- The global oxygen scavenger market is growing regionally, driven by rising demand for shelf-life extension, oxidation control, and expanding applications across food & beverage, pharmaceutical, packaging, and industrial processes. Asia Pacific is the largest regional market, supported by rapid industrialization, expanding food processing and pharmaceutical manufacturing, growing packaged food consumption, and increasing adoption of advanced oxygen-control technologies across China, India, Japan, South Korea, and Southeast Asia. North America holds the second-largest share, supported by established food & beverage and pharmaceutical industries, advanced packaging technologies, industrial water treatment, and increasing demand for reliable oxygen-control solutions. Europe is supported by demand for oxygen scavengers across food packaging, pharmaceutical, chemical, and industrial applications, along with growing adoption of sustainable and advanced packaging technologies. Meanwhile, South America and the Middle East & Africa are seeing rising demand, driven by industrialization, expanding food and pharmaceutical production, infrastructure development, and growing adoption of oxygen-control technologies across emerging markets.

- The Asia Pacific oxygen scavenger market accounted for 36.5% of revenue in 2026, driven by rapid industrialization, expanding pharmaceutical and food & beverage manufacturing, growing packaging applications, and increasing demand for advanced oxygen-control solutions across the region.

- The inorganic segment dominated the oxygen scavenger market in 2026, accounting for a 60.6% share of the overall market, in terms of value, owing to its effective oxygen absorption, established adoption, and widespread use across food & beverage packaging, pharmaceutical, and industrial applications.

- The liquid segment accounted for the highest share (48.7%) in terms of value in 2026, owing to its rapid oxygen removal, ease of application, and widespread use across power, oil & gas, chemical processing, and other industrial applications.

- The food & beverage application segment accounted for the largest share (24.9%) of the oxygen scavenger market in terms of value in 2026, owing to increasing demand for extended shelf life, oxidation control, product quality preservation, and protection of oxygen-sensitive, packaged foods and beverages.

- Ecolab and Mitsubishi Gas Chemical Company, Inc. were identified as star players in the global oxygen scavenger market, supported by their strong product portfolios, technological capabilities, and established presence across key oxygen-control applications.

- Advancion Corporation, Plastipak Holdings, Inc., Desiccare, Inc., and KHS Group, among others, have established positions in specialized applications and niche segments of the oxygen scavenger market, highlighting their potential as emerging market participants.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=101926191

The oxygen scavenger market is expanding, driven by the growing need for efficient oxygen removal and protection systems across end-user industries such as food & beverage, pharmaceutical, power, oil & gas, chemical, and pulp & paper. The oxygen scavenger meets the high-quality requirements of diverse, ultra-demanding applications because of its versatile properties, including high oxygen absorption capacity, oxidation prevention, odor and flavor preservation, char point reduction, corrosion resistance, and compatibility with a wide array of packaging and industrial systems. In addition, rising safety and product-quality standards, growing consumption of packaged and processed foods, increased pharmaceutical manufacturing, rising demand for corrosion inhibitors in industrial systems, and the adoption of advanced packaging technologies are also fueling market growth. Also, with the development of advanced oxygen-scavenging materials and active packaging technologies, premium oxygen scavengers are now being developed, offering higher absorption efficiency, better stability, longer protection duration, better compatibility with packaging materials, and more reliable performance even under tough storage and transportation conditions. Building on these innovations, advanced oxygen scavenger technology has become an integral component of today's packaging and industrial systems to prevent oxidation, improve industrial efficiency, preserve product quality, and extend shelf life.

Inorganic oxygen scavengers are expected to be the fastest-growing type during the forecast period.

Inorganic oxygen scavengers are expected to be the fastest-growing type in the oxygen scavenger industry, primarily because of their high oxygen absorption rate, excellent reaction efficiency, and protection against oxidation. Inorganic oxygen scavengers are specially formulated to remove residual dissolved oxygen and deliver optimal performance across diverse packaging and industrial applications. Inorganic oxygen scavengers are highly needed in food & beverage, packaging, pharmaceutical, power generation, oil & gas, chemical processing, and pulp & paper applications. A key driver of inorganic oxygen scavenger use is the growing demand for longer shelf life, higher product quality, corrosion prevention, and oxygen suppression. High efficiency across different temperatures and operating conditions, along with suitability for various industrial and packaging systems, is also a key driver of growth across end-use applications.

Resin is expected to be the fastest-growing form during the forecast period.

During the forecast period, resin is expected to be the fastest-growing form in the oxygen scavenger market. This growth is largely driven by its high oxygen absorption rate, easier integration into packaging materials, stable performance, and strong oxygen-protection ability over long periods. Resin-based oxygen scavengers are used mainly in food & beverage packaging, pharmaceutical packaging, chemical products, and other applications that require high oxygen protection. Rising market demand for longer shelf life & better product quality with advanced active packaging solutions has led to growing opportunities for resin-based applications. Rising investments in innovative packaging technologies and the development of oxygen-scavenging polymers are also boosting demand for resin-based oxygen scavengers in several end-use industries.

Pharmaceutical is expected to be the fastest-growing end-use industry during the forecast period.

Pharmaceutical is expected to be the fastest-growing end-use industry in the oxygen scavenger market, primarily because products must be protected from oxidation and degradation to maintain stability, quality, and shelf life. Oxygen scavengers are used extensively during pharmaceutical packaging for tablets, capsules, nutraceuticals, sensitive drugs, and other oxygen-sensitive products. Increasing demand for pharmaceutical products, stringent quality and stability requirements, growing concerns about product degradation, and increasing use of advanced packaging solutions are driving demand for oxygen scavengers in the pharmaceutical industry. In addition, growing investments in new pharmaceutical manufacturing plants and advanced packaging technologies are expected to increase oxygen scavenger use in pharmaceutical applications.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=101926191

The Asia Pacific is expected to be the fastest-growing region during the forecast period.

The Asia Pacific region is projected to be the fastest-growing regional market for the global oxygen scavenger market during the forecast period. Rapid industrialization and urbanization, a growing manufacturing sector, and rising investments in various applications are expected to drive demand for oxygen scavengers in the region. Countries like China, India, Japan, South Korea, and many Southeast Asian economies expanding industrial & manufacturing bases are increasing demand for oxygen scavenging and protection solutions, which is expected to boost growth in the region's oxygen scavenger market. Food & beverage packaging, pharmaceutical manufacturing, power generation, oil & gas treatment, chemical manufacturing, and pulp & paper applications are most likely to exhibit increasing use of oxygen scavengers during the forecast period. Beyond this, growing demand for product shelf-life extension, oxidation prevention, corrosion protection, product stability, and innovative packaging methods is also creating growth opportunities for the market in the Asia Pacific region.

Industrialization, rapid manufacturing, and investments are rapidly increasing in the food & beverage, pharmaceutical, oil & gas, chemical, and pulp & paper industries in the Asia Pacific region. Countries like China, India, and Japan are investing heavily in pharmaceutical manufacturing, food processing, industrial infrastructure, and advanced packaging systems. These countries are expanding packaged food manufacturing, pharmaceutical production, and industrial plants, which in turn creates demand for effective oxygen removal & protection solutions.

DELRAY BEACH, Fla., Oct. 12, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the rodenticides market is estimated to be USD 6.61 billion in 2026 and is projected to reach USD 8.83 billion by 2031, at a CAGR of 6.0% from 2026 to 2031.

Rodenticides Market Size & Forecast

- Market Size Available for Years: 2021–2031

- 2026 Market Size: USD 6.61 billion

- 2031 Projected Market Size: USD 8.83 billion

- CAGR (2026–2031): 6.0%

Rodenticides Market Trends & Insights:

- The rodenticides market is experiencing strong growth, driven by increasing urbanization, commercial and agricultural activity, and rising rodent infestations in warehouses, farms, and residential areas. Other forces shaping the dynamics and growth of this market include regulation, increasing awareness of health and economic risks, and the need for safe, effective, and sustainable pest-control solutions.

- North America accounted for the largest revenue share (31.3%) of the rodenticides market in 2025.

- By type, the software & services segment is expected to register the highest CAGR of 6.6% from 2026 to 2031.

- By mode of application, the pellets segment is expected to register the highest CAGR during the forecast period.

- By target rodent type, the mice segment is projected to exhibit the highest CAGR of 6.2% during the forecast period.

- By end use, the urban centers segment is estimated to dominate the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=189089498

The rodenticide market is experiencing growth due to rising rodent infestations in urban, suburban, and commercial areas. The increasing population is contributing to these infestations, particularly in urban and suburban settings, as well as in commercial spaces. The primary factor driving this growth is the heightened presence of rodents in urban, commercial, and industrial areas, which is attributed to deteriorating infrastructure and the rapid expansion of the food and beverage and logistics sectors. Additionally, stringent food safety and public health regulations have compelled businesses to implement more effective measures for rodent control. There is also a growing demand for eco-friendly, low-toxicity rodenticides, along with intelligent, data-driven monitoring solutions, which are making pest management more efficient, targeted, and compliant. These factors contribute to the sustained expansion of the market.

By type, chemical segment to hold significant market share.

The chemical segment is estimated to hold a significant share of the rodenticides market, by type, due to the proven efficacy and broad availability of chemical rodenticides. Both anticoagulant and non-anticoagulant rodenticide formulations are commonly used in residential, commercial, and agricultural settings for effective rodent control. Their effectiveness, ease of use, and adherence to regulations make them the preferred choice for professional pest-control operators. Additionally, with the introduction of safer chemicals, known as bio-rodenticides, the industry is likely to continue the production and use of traditional rodenticides. Some of the major manufacturers of rodenticides are Bell Laboratories, Inc. (US), Neogen Corporation (US), Liphatech, Inc. (US), JT Eaton & Co., Inc. (US), and Abell Pest Control (Canada).

By mode of application, pellets segment to hold significant market share during forecast period.

The pellets segment is estimated to hold a significant share of the rodenticides market due to the convenience, effectiveness, and versatility of pelletized rodenticides. Pellet formulations are most often chosen by professional pest-control operators and homeowners alike for use in the urban, commercial, and agricultural management of rodent populations. Because they allow controlled-dose applications, the risk of over-application can be reduced. They can then be placed in bait stations or other targeted applications for maximum efficacy. The inherent stability and long shelf-life make pellets even more appealing. These rodenticide products exist in both anticoagulant and non-anticoagulant chemistries, allowing flexibility in meeting regulatory and safety requirements. These very characteristics of convenience, efficacy, and compliance continuously reinforce the dominance of pellet formulations, thus making them the preferred application mode in an array of sectors.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=189089498

By region, Europe to account for significant market share.

Europe is expected to hold a significant share of the global rodenticides market, driven by increasing rodent infestations in urban, industrial, and agricultural sectors, as well as stringent food safety and public health regulations. The rise in rodent populations across the continent, paired with these regulations, is incentivizing Europe to become a major player in the worldwide rodenticides market. Factors such as well-developed pest control services, efficient distribution systems, and the acceptance of both chemical and pellet-based rodenticides further enhance this scenario. Additionally, there is a growing demand for eco-friendly and low-toxicity formulations, alongside the development of smart monitoring systems and data-driven pest management solutions, which improve both efficiency and compliance. These elements continue to strengthen Europe's leading position and contribute to the ongoing growth of the global rodenticides market.

Top Companies in the Rodenticides Market

The report profiles key players such as BASF SE (Germany), Bayer AG (Germany), Syngenta AG (Switzerland), UPL Limited (India), Neogen Corporation (US), JT Eaton & Co., Inc. (US), PelGar International Ltd. (UK), SenesTech, Inc. (US), Impex Europa S.L. (Spain), Rentokil Initial plc (UK), Anticimex AB (Sweden), Ecolab Inc. (US), Rollins, Inc. (US), India Pesticides Limited (India), and Sumitomo Chemical Co., Ltd. (Japan).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=189089498

Investment Funding Context

The rodenticides market is witnessing investment activity toward alternative and next-generation rodent-control technologies. SenesTech, Inc., a developer of fertility-control solutions for rodent population management, raised USD 4.4 million in gross proceeds through a warrant exercise in July 2025 and subsequently raised USD 6.3 million in gross proceeds in August 2025. The company is commercializing Evolve Rat and Evolve Mouse, which use fertility-control technology as an alternative to conventional lethal rodenticides. Such financing activity indicates continued capital support for innovative rodent-management technologies that seek to complement or provide alternatives to conventional anticoagulants and non-anticoagulant rodenticides.

Revenue Shift Context

The rodenticides market is estimated to be USD 6.61 billion in 2026 and is projected to reach USD 8.83 billion by 2031, at a CAGR of 6.0% from 2026 to 2031. The market is experiencing revenue growth driven by increasing rodent infestations, urbanization, expansion of food-processing and storage facilities, agricultural losses, and growing awareness of food safety and public health risks associated with rodents. Anticoagulant rodenticides, including brodifacoum, bromadiolone, and difenacoum, remain widely used due to their established efficacy, while non-anticoagulant solutions such as cholecalciferol and zinc phosphide provide alternatives for specific pest-control requirements. Demand is also supported by the adoption of professional pest-management services and increasing regulatory emphasis on effective and responsible rodent control. Asia Pacific represents an important growth region, supported by rapid urbanization, expanding agricultural activity, food-storage infrastructure, and increasing pest-management requirements.

Mergers and Acquisitions

Mergers and acquisitions in the rodenticides market are increasingly focused on strengthening product portfolios, expanding geographic presence, enhancing manufacturing capabilities, and accessing innovative rodent-control technologies. Companies are seeking to complement established anticoagulant rodenticides with non-anticoagulant, species-specific, and fertility-control solutions. Acquisitions and strategic investments also enable companies to broaden distribution networks, strengthen regulatory capabilities, and accelerate the commercialization of new products. The need for effective rodent management across agricultural, residential, commercial, and food-related applications is expected to support continued consolidation and strategic investment across the rodenticide and broader pest-management industry.

RODENTICIDES MARKET: MERGERS AND ACQUISITIONS, APRIL 2025–APRIL 2026

Company Revenue Share Details

The top five players in the rodenticides market—BASF SE (Germany), Bayer AG (Germany), Syngenta AG (Switzerland), Rentokil Initial plc (UK), and UPL Limited (India)—collectively account for approximately 34–40% of the market revenue, indicating a moderately concentrated competitive landscape. The remaining 60–66% is distributed among other global and regional manufacturers, specialized rodenticide companies, and pest-management providers. The presence of major agrochemical companies alongside specialized pest-control operators reflects the diverse competitive structure of the market. Competitive positioning is influenced by established rodenticide product portfolios, geographic reach, distribution networks, regulatory approvals, product innovation, and the development of alternative rodent-control technologies.

DELRAY BEACH, Fla., Oct. 12, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the global Low Power Brushless DC Motors Market size is projected to grow from USD 6.59 billion in 2026 to USD 9.69 billion by 2031 at a compound annual growth rate (CAGR) of 8.0% during the forecast period.

Browse 150 market data Tables and 60 Figures spread through 220 Pages and in-depth TOC on 'Low-Power Brushless DC Motor Market — Global Forecast to 2031.'

The global Low-Power BLDC Motor Market is thriving as manufacturers in industrial automation, robotics, automobile manufacturing, consumer electronic devices, HVAC systems, medical equipment, and other sectors continue to emphasize features such as energy efficiency, compact design, precise motion control, and dependable operation. Low-power BLDC motors are gaining widespread use for smooth, controlled device operation, offering lower power consumption, low maintenance needs, longer lifespan, and improved speed and torque control. The expansion of demand for low-power BLDC technology is driven by the need to replace older brushed motors, improve the performance of devices using this type of motor, and, in general, pursue the trend of miniaturization and product electrification. The growing use of automatic systems, battery-powered machines, electric cars, and energy-saving appliances is driving demand for compact motors.

Advances in electronic commutation, sensorless control, Hall-effect technology, integrated motor drivers, encoders, the Internet of Things, and other motor-control technologies have shaped the market. Modern BLDC systems combine the motor and control unit to ensure proper speed and torque management and improve overall efficiency. Connecting the motor system with controllers and sensors enables condition monitoring, remote communication, automated control and forecasting. Advancements in compact motor design, high-power-density technology, thermal management, and specialized designs have supported the popularity of low-power BLDC engines in robotics, medical equipment, HVAC systems, industrial automation, the automotive industry, and other technology sectors.

Low Power Brushless DC Motors Market Size & Forecast:

- Market Size Available for Years: 2026–2031

- 2025 Market Size: USD 6.11 billion

- 2031 Projected Market Size: USD 9.69 billion

- CAGR (2026–2031): 8.0%

Low Power Brushless DC Motors Market Trends & Insights:

- The Asia Pacific is expected to register the highest CAGR of 8.8% during the forecast period.

- By power rating, the 100 W segment is expected to register the highest CAGR of 8.4% during the forecast period.

- By speed, the 1500–3000 RPM segment is expected to register the highest CAGR of 8.4% during the forecast period.

- By application, the renewable energy segment is expected to register the highest growth during the forecast period.

- NIDEC Corporation, Regal Rexnord, and Maxon were identified as star in the Low-Power Brushless DC Motor Market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191199574

100 W segment is likely to record the highest CAGR during 2026–2031.

The growth in the market for the 100 W segment is expected to be immense owing to the increasing acceptance of low-power BLDC motors in the making of compact products that require high efficiency, precise speed regulation, and minimum maintenance. BLDC motors are used in consumer electronics, HVAC, medical and laboratory equipment, robotics, and office automation systems. The general trend toward miniaturizing battery-powered products requires motors that deliver high performance with low energy consumption. Moreover, the shift from conventional brushed DC motors to electronically commutated BLDC motors is a major driver of 100 W motor adoption across a wide range of industries.

1,500–3,000 RPM is likely to record the highest CAGR during 2026–2031.

The BLDC motors segment operating between 1,500 and 3,000 revolutions per minute is projected to grow significantly, as this technology offers an optimal balance of speed and control across multiple markets, from HVAC systems to pumps and medical devices. BLDC motors are increasingly used in equipment that requires stable, precise performance, such as household appliances, industrial automation, robotics, and other compact motion systems. Furthermore, the growing popularity of energy-efficient, automated machinery drives demand for noise-free engines that require little maintenance. Modern manufacturers design BLDC motors to meet specific application requirements and actively implement the latest advances in electronic commutation, sensorless control, Hall-effect sensing, integrated drivers, and compact engines.

Asia Pacific is expected to be the fastest-growing region in the Low-Power Brushless DC Motor Market during the forecast period.

The Low-Power Brushless DC Motor Market in the Asia Pacific region is expected to grow at the fastest rate, driven by rapid industrial development, growth in the manufacturing sector, increasing automation, and a growing need for energy savings. The strong presence of the electronics, automotive, domestic appliance, HVAC, and precision manufacturing industries in the region has driven rapid adoption of compact, efficient BLDC motors. Countries such as China, Japan, South Korea, India, and ASEAN countries have invested heavily in robotics, industrial automation, electric transportation, smart appliances, and battery devices, driving rising demand for low-power motor technologies. In addition, electronics production growth and wider adoption of energy-saving HVAC systems and automation equipment will undoubtedly promote BLDC motor use, with precise speed control, low maintenance requirements, compact size, and high efficiency.

Top Companies in Low Power Brushless DC Motors Industry:

The Low Power Brushless DC Motors Industry include NIDEC Corporation (Japan), MinebeaMitsumi Inc. (Japan), TransDigm Group (US), Regal Rexnord (US), AMETEK Inc. (US), Maxon (Switzerland), FAULHABER Group (Germany), ElectroCraft (US), Oriental Motor (Japan), Bühler Motor (Germany), Greensky Power (China), Allient Inc. (US), G.W. Lisk Company (US), and TT Motor (Shenzhen) Industrial (China). These companies are strengthening their market positions through BLDC motor portfolio expansion, product innovation, miniaturization, energy-efficiency improvements, integrated motor-drive solutions, application-specific customization, geographic expansion, and investments in automation, robotics, medical, aerospace & defense, oil and gas, renewable energy and other applications.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=191199574

Low Power Brushless DC Motors Market - Investment & funding + Merger & Acquisition

Investment Funding Context

Investment in the low-power brushless DC motor sector is rising as more electric motor companies recognize the growing demand for energy-efficient, compact, affordable, application-specific motion solutions. Investments aim to either increase BLDC motor production or support product development, automation, or supply chain improvements. For example, Greensky Company Power Limited announced plans to invest USD 120 million in producing BLDC and stepper motors in 2025, focusing on 50 W–750 W BLDC motors. In the Indian market, Motorama EV has raised INR 1.12 crore in 2025 to promote the production and development of rare-earth-free BLDC motors.

Revenue Shift Context

The Low-Power Brushless DC Motors Market is gradually moving away from traditional standalone motor products toward an efficiently integrated solution tailored to motion control applications. This transition is enabled by demand for smaller motors that require precise speed and torque control and consume less energy, require less maintenance, and have a longer lifespan. Furthermore, motor manufacturers are increasingly combining BLDC motors with drivers, control systems, sensors, encoders, gearboxes, and communication systems to get better efficiency and performance. The adoption of automation, robotics, electrification, HVAC, medical equipment, and portable devices and systems will also shift sales toward more expensive motors and integrated drives. All this indicates growing interest in making motors more efficient, smaller, integrating various components into one system, and customizing them to better suit customers' motion-control needs.

Mergers and Acquisitions

Mergers and acquisitions in the Low-Power Brushless DC Motors Market serve specific purposes: expanding motor portfolios, enhancing motion-control sophistication, and gaining better access to certain technologies and markets. Companies achieve these goals through acquisitions or meaningful investments to build expertise in areas such as precision motors, integrated drives, gearboxes, controllers, and other motion technologies. Regal Rexnord's acquisition of Altra Industrial Motion broadened its portfolio of precision motion-control businesses, and AMETEK's acquisition of Bison Gear & Engineering in May 2023 provided around USD 80 million in annual income, expanding its electromechanical portfolio. These transactions clearly indicate a trend of continually improving integration of BLDC motors with various motion-control technologies.

Low Power Brushless DC Motors Market: Mergers and Acquisitions, January 2025–June 2025

Company Revenue Share Details

Competition in the Low-Power Brushless DC Motors Market is constant, as market leaders in manufacturing and motion control pursue different strategies to promote their products and services across industrial applications, robotics, automotive, consumer electronics, HVAC, and medical. Several companies profiled among the key participants in the low-power BLDC motor market, such as NIDEC Corporation, MinebeaMitsumi Inc., TransDigm Group, Regal Rexnord, and AMETEK Inc.

Euro Tech Holdings Company Limited Announces The Company has signed a 50/50 Joint Venture Agreement With Sea Clean AS In Norway

HONG KONG, Oct. 12, 2026 /PRNewswire/ -- Euro Tech Holdings Company Limited (Nasdaq: CLWT) today announces its entry into Norway through a 50/50 joint venture ("JV") agreement signed between Sea Clean AS ("Sea Clean") and its wholly owned subsidiary, Euro Tech Global Pte Ltd. CleanPACT Environmental and Marine Engineering AS ("CleanPACT") is the name of the JV company.

CleanPACT will serve as a Customer Experience Center for port ballast water treatment, offering customers hands-on demonstrations, expert servicing, realistic simulations, and tailored training with the Company's next-generation mobile hybrid system (PortoBallast is the trade mark of the system) designed to treat ballast water from UV and electrolysis type ballast water treatment systems that do not meet discharge compliance requirements aboard vessels. The JV combines the Company's technology, expertise, and capabilities with Sea Clean's local knowledge, port experience, and market reach to clients.

Sea Clean is now setting up and commissioning the PortoBallast which has recently arrived at Sea Clean's port site in Torvastad, Norway.

In addition, the new JV will promote the PortoBallast across Scandinavia as a stepping stone to entering the European market. The Company believes this positioning will give it a new sales platform for global promotion.

About Sea Clean

Sea Clean is a Norwegian provider of ballast water treatment solutions for the maritime industry. As an authorized agent of electrolysis-type Ballast Water Treatment System, they handle distribution, service, and maintenance of ballast water treatment systems worldwide. To date they've served more than 2300 vessels.

Their team of experienced technicians provides comprehensive service solutions, from system installation to annual compliance checks, ensuring vessels meet international ballast water management standards.

Website: https://www.seaclean.no

Forward Looking Statements

Certain statements in this news release regarding the Company's expectations, estimates, present view of circumstances or events, and statements containing words such as estimates, anticipates, intends, or expects, or words of similar import, constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements indicate uncertainty and the Company can give no assurance with regard to actual outcomes. Specific risk factors may include, without limitation, having the Company's offices and operations situated in Hong Kong and China, doing business in China, competing with Chinese manufactured products, competing with the Company's own suppliers, dependence on vendors, and lack of long term written agreements with suppliers and customers, development of new products, entering new markets, possible downturns in business conditions, increased competition, loss of significant customers, availability of qualified personnel, negotiating definitive agreements, new marketing efforts and the timely development of resources. See the "Risk Factor" discussions in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 20-F for its fiscal year ended December 31, 2025.

SOURCE EURO TECH HOLDINGS COMPANY LIMITED

Share this article

The Frost Radar™: SCADA for Industrial Control Environments, 2026 recognizes the FrameworX architecture, with AI engineering built on a Unified Namespace and knowledge graph.

HOUSTON, Oct. 12, 2026 /PRNewswire/ -- Frost & Sullivan has named Tatsoft a Visionary Leader in the Frost Radar™: SCADA for Industrial Control Environments, 2026. The Frost Radar™ benchmarks supervisory control and data acquisition (SCADA) platforms on two indices, innovation and growth, and Visionary Leaders are the companies with a strong balance of both.

"Tatsoft's combination of modern software architecture, embedded AI capabilities, and commercially disruptive licensing earns it a position among the Visionary Leaders, reflecting a strong innovation profile and significant growth potential," said Sebastian Trolli, Research Director and Principal Analyst, Industrial Automation & Software, at Frost & Sullivan.

Frost & Sullivan's profile of Tatsoft centers on FrameworX 10.1, released in May 2026, and on the architecture underneath it: a current .NET runtime, WebAssembly, so one build runs on desktop, web and mobile, deployment on Windows, Linux and Docker, and a Unified Namespace (UNS) and knowledge graph built into the platform. In practice, FrameworX 10.1 runs on .NET 10, a plant's data sits in one namespace, and engineers extend the application in C#, VB.NET and Python 3. Frost & Sullivan describes the platform as "one of the most current architectures in this Frost Radar™ analysis."

FrameworX is AI-Native by architecture: MCP servers for the Designer, the Console and the Runtime, plus an AI Tutor that adapts to each user's knowledge and experience, all released and supported today. MCP, the Model Context Protocol, lets AI agents and human engineers work on the same platform surfaces. With the FrameworX AI Designer, the AI works on the actual project and its tags in a cooperative and protected environment: every change is visible, and nothing happens behind the scenes or without an engineer's approval.

The FrameworX AI Runtime works with standard cloud models and equally with models installed on a local network with no connection to the internet. Each deployment can be given its own set of MCP Tools, so engineers and plant owners decide exactly what information operators and other applications can reach. Frost & Sullivan notes that SCADA customers often face data sovereignty, latency, cybersecurity and connectivity constraints that make cloud-only AI difficult. FrameworX meets that requirement: it connects to a model on the local network, or to external systems under cybersecurity best practices.

"Frost & Sullivan looked past the feature list to the architecture, and that is where FrameworX was designed from the start," said Marc Taccolini, founder and CEO of Tatsoft. "FrameworX is one unified and integrated platform, with every module included and with the performance and reliability industrial operations require, at a cost that keeps your company competitive."

Frost & Sullivan ties the architecture to modernization. Its profile says FrameworX gives Tatsoft "a software-architecture story that is stronger than traditional HMI modernization," and that unlimited-capacity licensing "lowers switching friction for customers consolidating multiple legacy SCADA or connectivity licenses." To make the upgrade of brownfield systems practical, Tatsoft is releasing a migration service built to update the technology with high reliability and at low cost. The application the plant runs stays the same; the platform and tools underneath it evolve. Automation and decades of experience make the process reliable.

The migration method and results are shown in the film "How to Migrate a Legacy SCADA Application: AI Builds the Screens, You Own the Model": https://youtu.be/VSTt4nkqK1s

Any plant running a legacy HMI or SCADA application can send Tatsoft a read-only copy of it. The copy is held in confidence, used only to evaluate the upgrade, and the report goes only to its owner. The assessment is free and takes 2 to 5 working days. If the plant goes ahead, the migration is a fixed price quoted from that report, and it is paid only if the plant accepts the result of the first migration pass. Specific field integrations, validation and field commissioning are done by the plant or contracted through Tatsoft's network of system integrators.

Send an application for assessment: https://tatsoft.com/migrate-to-frameworx/

The FrameworX engineering tool is available for download: https://tatsoft.com/fx-101/#download

About Tatsoft

Tatsoft is an independent software company with nearly 30 years of industrial DNA. FrameworX unifies SCADA, HMI, industrial IoT (IIoT) and Historian in one platform, with 100+ connectors, an ISA-95 Unified Namespace and an interface in 12 languages. Founded in 2009 by the team that designed InduSoft (now AVEVA Edge) in 1997, Tatsoft counts 5,000+ deployments and is headquartered in Houston, Texas, with a global network of distributors and integration partners.

FrameworX. AI builds and runs the industrial solution.

Aim High. Start Simple. Scale Without Limits.

Source: Frost & Sullivan, Frost Radar™: SCADA for Industrial Control Environments, 2026.

Media contact: Isabela Taccolini, Marketing, Tatsoft LLC, [email protected]

SOURCE Tatsoft

Share this article

Veteran sports and business leader will help identify and develop opportunities across GameAbove Sports, 21X SPORTS and CapStone's broader sports portfolio

ASPEN, Colo., Oct. 12, 2026/PRNewswire/ -- CapStone Holdings Inc. ("CapStone") today announced that Jeff Genyk has joined the company as head of sports ventures. Working across the portfolio and in collaboration with existing leadership, Genyk will help identify, evaluate and develop opportunities across GameAbove Sports, 21X SPORTS and other ventures across the industry.

"Jeff brings a valuable combination of business experience, sports leadership and relationship-building skills," said Ashley Beal, chief of staff at CapStone. "He understands how to lead people, evaluate opportunities and work across organizations, making him a strong fit to help advance CapStone's sports ventures through GameAbove Sports and 21X SPORTS."

Genyk brings leadership experience spanning business, collegiate athletics and sports media. Before entering college coaching, he spent a decade in private business. He later served as head football coach at Eastern Michigan University and held coaching and football operations roles at Northwestern University, the University of California, Berkeley, the University of Wisconsin and Vanderbilt University. His tenure included work with conference championship teams at Northwestern and Wisconsin. He also served as an ESPN color analyst for Atlantic Coast Conference football games.

"I am thrilled to join CapStone and work with Keith Stone and the broader team," Genyk said. "CapStone has a proven record of building businesses and positively affecting communities. I look forward to bringing my experience across business, athletics and media to help develop opportunities throughout its sports portfolio."

The appointment strengthens CapStone's leadership team as the company expands activity across the sports industry. GameAbove Sports invests in teams, companies and initiatives while supporting athlete management, partnerships and youth development. 21X, formerly known as Structurely, recently launched 21X SPORTS, a business vertical owned by 21X and developed in partnership with GameAbove Sports. The platform is designed to help organizations pursue incremental revenue from existing fan and customer relationships.

Genyk holds an MBA from Western Michigan University and a master's degree in education and social policy from Northwestern University. He earned a bachelor's degree in business administration from Bowling Green State University, where he played quarterback and punter.

About 21X

21X, formerly known as Structurely, is an AI engagement infrastructure company that helps businesses grow revenue, improve customer experiences and operate more efficiently. Built on more than a decade of experience in real customer conversations, 21X uses AI across voice, SMS and email to respond, understand intent, guide customers toward the right next action and route appropriate opportunities to live personnel. The company serves organizations in real estate, mortgage lending, life insurance, aviation and sports. Learn more at 21Xai.com.

About GameAbove Sports

GameAbove Sports focuses on global business development and strategic investments across teams, franchises, leagues, events, related companies and community initiatives. Learn more at gameabovesports.com.

About CapStone Holdings Inc.

CapStone Holdings Inc. is a family office-structured investment firm providing investment capital and strategic support across technology, financial technology, real estate and sports. Its portfolio includes GameAbove and 21X. CapStone and its founders have invested across a range of industries for more than 35 years and support focused philanthropic initiatives. For more information, visit capstoneholdingsinc.com.

SOURCE CapStone Holdings, Inc.

Share this article

In-store costume contest, giveaways and special offers bring Halloween fun to participating Rural

King stores, with two $500 grand prizes up for grabs

MATTOON, Ill., Oct. 12, 2026 /PRNewswire/ -- Rural King, a family-owned retailer dedicated to the rural lifestyle, is inviting customers and their animals to get into the Halloween spirit during Pet-O-Ween, a free in-store pet and livestock costume contest taking place Saturday, Oct. 24, from 10 a.m. to 2 p.m. at participating Rural King stores.

Customers can dress up their animals and enter them in one of two categories, Pet or Livestock, with Rural King associates judging the costumes beginning at 1 p.m. Pet-O-Ween will also feature giveaways and special in-store offers throughout the day.

"Pet-O-Ween gives our customers a fun way to celebrate Halloween with the animals that are such an important part of their families, farms and everyday lives," said Rural King Interim Vice President of Marketing Cody Kay. "We love seeing the creativity our customers bring to the costume contest, and we're looking forward to welcoming everyone into our stores for a memorable day."

At each participating store, first-, second- and third-place winners will be selected in both the Pet and Livestock categories. Every winner will receive a 15-inch XL Billie Goat plush, along with coupons redeemable for eligible Purina pet food for Pet category winners or Nutrena livestock feed for Livestock category winners. First-place winners will receive six coupons, second-place winners will receive four and third-place winners will receive two.

This year's Billie Goat plush honors the memory of Billie Jean Lawyer, mother of Rural King Pet Buyer Blayne Lawyer. Billie Jean was a lifelong animal lover whose family farm was home to goats, sheep, pigs, chickens, ducks, dogs, cats and a donkey, with goats holding a particularly special place in her heart. The tribute inspired this year's Billie Goat giveaway as a way to celebrate her love of animals and connection to Rural King.

The competition will continue beyond the store level. One Pet winner and one Livestock winner will be selected from the pool of store-level winners across participating locations, with each grand prize winner receiving a $500 Rural King gift card. Grand prize winners will be announced on Rural King's Facebook page.

Pet-O-Ween festivities begin at 10 a.m. with additional giveaways and offers, including a free Mini Billie Goat plush for the first 50 customers and 50% off eligible Purina pet treats that fit inside a limited-edition Rural King Pet-O-Ween "Trick or Treat" bag for the first 100 customers. Customers can also buy eight and get four free on select 5.5-ounce Friskies single cans of wet cat food while supplies last.

Pet-O-Ween will be held Oct. 24 from 10 a.m. to 2 p.m. at participating Rural King stores, excluding Ohio locations. Offers are valid in stores only while supplies last. Additional exclusions and restrictions may apply. Customers should check with their local Rural King for additional details. For more information, visit Ruralking.com, RKguns.com or RKtractors.com.

Media images from last year's Pet-O-Ween events are available here.

About Rural King, Inc.

Rural King, also known as RK Holdings, LLP, planted its roots as America's Farm and Home Store in Mattoon, Illinois, in 1960. Since that time, Rural King has grown to more than 160 stores in 18 states. Rural King offers the lowest prices on a broad range of essential goods, food, feed, seed and other farm and home necessities to the communities we serve throughout Alabama, Georgia, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan, Mississippi, Missouri, North Carolina, New York, Ohio, Pennsylvania, South Carolina, Tennessee, Virginia, and West Virginia. We welcome and encourage everyone to enjoy our longstanding tradition of offering free popcorn and coffee every time you visit our stores.

SOURCE Rural King

Share this article

MOULTONBOROUGH, N.H., Oct. 12, 2026 /PRNewswire/ -- Castle in the Clouds is pleased to announce the return of their popular annual holiday tradition, Christmas at the Castle. Christmas at the Castle is a series of events held at the National Historic Landmark Lucknow Estate across three weekends at the start of the holiday season. This year, the season's theme is "Old-Fashioned New England Christmas," offering visitors a holiday experience perfectly tailored to the backdrop of the historic home.

This year, Castle in the Clouds is offering visitors three different ways to experience the magic of Christmas at the Castle. The holiday festivities begin with the Christmas Preview Party on the evening of Friday, November 20, at 4:00 p.m. During the preview, guests can visit Lucknow Mansion and experience the holiday festivities before the general public. The Preview party will include cocktails, hors d'oeuvres, carolers, and first access to the Artisan Fair held in the Carriage House. Tickets for this exclusive fundraising event are limited, with proceeds benefiting the nonprofit mission of Castle Preservation Society.

The public Christmas at the Castle events and activities begin the next day. Every Saturday and Sunday from November 21 through December 6 from 10:00 a.m. to 4:00 p.m., visitors can spend the day exploring the Castle, admiring the holiday décor provided by local businesses, and participating in holiday activities. In addition to the seasonal decorations, Christmas at the Castle promises holiday spirit and family fun. Visitors can shop with local vendors at the Artisan Fair, take a photo with Santa, create holiday crafts, and enjoy complimentary hot cocoa and cookies. The Carriage House Restaurant will be open, offering the addition of a holiday lunch to the Christmas at the Castle experience.

After a successful introduction last year, Castle in the Clouds is also hosting Christmas at the Castle Twilight Tours. On Christmas at the Castle dates at 3:00 p.m., visitors can enjoy a special dusk tour of Lucknow Mansion illuminated by holiday lights. Tickets for Twilight Tours are limited to allow a more intimate experience.

"Christmas at the Castle is a beloved tradition at Castle in the Clouds, and we are delighted to host this time-honored event again this year," said Charles Clark, Executive Director of Castle in the Clouds. "Our theme this year is a perfect fit for the historic estate and aligns with our current museum exhibit about the history of the property. With exclusive opportunities for viewing like the Preview Party and Twilight Tours, we are excited to offer unique ways for new and returning visitors to experience Christmas at the Castle."

For more information or to purchase tickets for Christmas at the Castle, visit castleintheclouds.org/christmas-at-the-castle.

ABOUT CASTLE IN THE CLOUDS

As the premier historical museum in the beautiful Lakes Region of New Hampshire, Castle in the Clouds provides each visitor with a look into the past while providing contemporary comforts to make every visit memorable. Originally called Lucknow, this breathtaking 6,300-acre property was developed in 1913 by Thomas G. Plant, a wealthy shoe manufacturer, to create a luxurious lifestyle with state-of-the-art amenities, beautiful hand-made furnishings, and a large staff to run the estate. These days, visitors come from all around the world to tour the mansion and exhibit gallery, dine in the Carriage House Restaurant or Café in the Clouds, hike miles of hiking and walking trails maintained by partner organization the Lakes Region Conservation Trust, or enjoy one of our many programs and events. Operated by the Castle Preservation Society, a 501(c)(3) nonprofit organization celebrating its 20th anniversary in 2026, Castle in the Clouds is revered as a cultural and educational resource and listed on the National Register of Historic Places with national significance. Castle in the Clouds is also available as a fairytale wedding venue and versatile private event rental. For more information about Castle in the Clouds, visit castleintheclouds.org.

SOURCE Castle in the Clouds

Share this article